INmune Bio IncNASDAQ:INMB
- LAST PRICE6.2200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.8000/ 2
- Ask / Lots6.2500/ 1
- Open / Previous Close--- / 6.2200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INMB |
|---|---|---|
| 09:32 ET | 763 | 6.46 |
| 09:33 ET | 1746 | 6.49 |
| 09:42 ET | 1500 | 6.5 |
| 09:44 ET | 2503 | 6.44 |
| 09:46 ET | 3221 | 6.3803 |
| 09:48 ET | 300 | 6.41 |
| 09:50 ET | 700 | 6.44 |
| 09:51 ET | 100 | 6.44 |
| 09:53 ET | 1385 | 6.44 |
| 09:55 ET | 2512 | 6.4 |
| 09:57 ET | 7158 | 6.33 |
| 10:00 ET | 1700 | 6.352006 |
| 10:02 ET | 300 | 6.36 |
| 10:11 ET | 100 | 6.35 |
| 10:13 ET | 584 | 6.32 |
| 10:22 ET | 200 | 6.28 |
| 10:24 ET | 1000 | 6.275 |
| 10:29 ET | 100 | 6.28 |
| 10:31 ET | 900 | 6.3 |
| 10:33 ET | 607 | 6.31 |
| 10:36 ET | 300 | 6.29 |
| 10:40 ET | 518 | 6.345 |
| 10:49 ET | 210 | 6.375 |
| 10:51 ET | 309 | 6.39 |
| 10:56 ET | 400 | 6.4 |
| 10:58 ET | 516 | 6.4 |
| 11:00 ET | 368 | 6.38 |
| 11:07 ET | 4000 | 6.3 |
| 11:09 ET | 682 | 6.311 |
| 11:12 ET | 203 | 6.3 |
| 11:21 ET | 300 | 6.295 |
| 11:23 ET | 615 | 6.27 |
| 11:25 ET | 300 | 6.27 |
| 11:27 ET | 200 | 6.32 |
| 11:32 ET | 100 | 6.27 |
| 11:34 ET | 600 | 6.32 |
| 11:36 ET | 100 | 6.3 |
| 11:38 ET | 100 | 6.3 |
| 11:39 ET | 400 | 6.28 |
| 11:41 ET | 3976 | 6.26 |
| 11:48 ET | 1214 | 6.265 |
| 11:50 ET | 1151 | 6.265 |
| 11:54 ET | 153 | 6.27 |
| 11:56 ET | 400 | 6.3 |
| 11:59 ET | 472 | 6.29 |
| 12:01 ET | 400 | 6.29 |
| 12:03 ET | 100 | 6.29 |
| 12:06 ET | 491 | 6.27 |
| 12:08 ET | 448 | 6.29 |
| 12:26 ET | 2104 | 6.35 |
| 12:28 ET | 200 | 6.33 |
| 12:30 ET | 300 | 6.32 |
| 12:39 ET | 100 | 6.31 |
| 12:42 ET | 200 | 6.29 |
| 12:50 ET | 280 | 6.3094 |
| 12:51 ET | 300 | 6.284 |
| 12:53 ET | 100 | 6.27 |
| 01:02 ET | 1476 | 6.245 |
| 01:04 ET | 100 | 6.245 |
| 01:06 ET | 100 | 6.25 |
| 01:08 ET | 100 | 6.245 |
| 01:09 ET | 100 | 6.25 |
| 01:11 ET | 334 | 6.24 |
| 01:22 ET | 2837 | 6.21 |
| 01:24 ET | 130 | 6.23 |
| 01:33 ET | 200 | 6.22 |
| 01:40 ET | 100 | 6.22 |
| 01:42 ET | 100 | 6.2 |
| 01:51 ET | 1100 | 6.215 |
| 01:54 ET | 281 | 6.207 |
| 01:56 ET | 1343 | 6.195 |
| 01:58 ET | 1001 | 6.17 |
| 02:00 ET | 1070 | 6.1701 |
| 02:02 ET | 639 | 6.205 |
| 02:03 ET | 368 | 6.1855 |
| 02:05 ET | 650 | 6.2 |
| 02:07 ET | 300 | 6.18 |
| 02:14 ET | 1665 | 6.19 |
| 02:16 ET | 100 | 6.2 |
| 02:18 ET | 100 | 6.205 |
| 02:21 ET | 100 | 6.19 |
| 02:23 ET | 2145 | 6.1234 |
| 02:25 ET | 565 | 6.14 |
| 02:27 ET | 168 | 6.16 |
| 02:32 ET | 1300 | 6.19 |
| 02:34 ET | 344 | 6.19 |
| 02:36 ET | 3772 | 6.15 |
| 02:39 ET | 2700 | 6.14 |
| 02:41 ET | 435 | 6.14 |
| 02:43 ET | 290 | 6.11 |
| 02:45 ET | 2700 | 6.155 |
| 02:48 ET | 2174 | 6.15 |
| 02:52 ET | 2639 | 6.18 |
| 02:54 ET | 900 | 6.14 |
| 02:56 ET | 1200 | 6.14 |
| 02:59 ET | 459 | 6.1334 |
| 03:01 ET | 1389 | 6.16 |
| 03:03 ET | 5400 | 6.18 |
| 03:08 ET | 1622 | 6.15 |
| 03:12 ET | 654 | 6.19 |
| 03:14 ET | 2929 | 6.23 |
| 03:15 ET | 6550 | 6.24 |
| 03:17 ET | 2715 | 6.2305 |
| 03:26 ET | 233 | 6.21 |
| 03:28 ET | 100 | 6.22 |
| 03:30 ET | 1457 | 6.2499 |
| 03:32 ET | 2168 | 6.2459 |
| 03:33 ET | 100 | 6.23 |
| 03:35 ET | 285 | 6.212 |
| 03:42 ET | 300 | 6.23 |
| 03:46 ET | 1136 | 6.22 |
| 03:48 ET | 300 | 6.23 |
| 03:50 ET | 117 | 6.2499 |
| 03:51 ET | 100 | 6.24 |
| 03:53 ET | 400 | 6.2329 |
| 03:55 ET | 200 | 6.23 |
| 03:57 ET | 187 | 6.23 |
| 04:00 ET | 10219 | 6.22 |
Oct 31, 2024
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones*DJ INmune Bio 3Q Loss/Shr 60c >INMB, from 4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
4:05PM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 28, 2024
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB, from 8:00AM ET on Monday Oct 28, 2024 by Dow Jones
8:00AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 24, 2024
DJ INmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System Diseases, from 3:25PM ET on Thursday Oct 24, 2024 by Dow Jones
3:25PM ET on Thursday Oct 24, 2024 by Dow JonesINmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro(TM) Promotes Remyelination, from 3:03PM ET on Thursday Oct 24, 2024 by Dow Jones
3:03PM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
INmune Bio Inc | 137.9M | -2.9x | --- |
Rani Therapeutics Holdings Inc | 134.6M | -2.1x | --- |
Vigil Neuroscience Inc | 141.5M | -1.7x | --- |
Leap Therapeutics Inc | 132.8M | -1.7x | --- |
Inovio Pharmaceuticals Inc | 143.3M | -1.1x | --- |
Fibrobiologics Inc | 125.5M | -3.8x | --- |
Company Information
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Contact Information
- Headquarters
- 225 Ne Mizner Blvd, Suite 640BOCA RATON, FL, United States 33432
- Phone
- 858-964-3720
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Raymond Tesi
- Chief Financial Officer
- David Moss
- Chief Scientific Officer
- Mark Lowdell
- Independent Director
- Marcia Allen
- Independent Director
- J. Kelly Ganjei
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $137.9M |
|---|---|
Revenue (TTM) | $42.0K |
Shares Outstanding | 22.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.85 |
EPS | $-2.18 |
Book Value | $2.12 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | 3,283.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -98,921.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
